NEW CAUCUS IS NOT QUITE ONE FOR ALL

NEW CAUCUS IS NOT QUITE ONE FOR ALL Author: Jeffrey Mervis WASHINGTON--The latest battlefield in the ongoing war over priorities within the biomedical research community is the congressional Biomedical Research Caucus. The caucus, which has signed up 18 members of Congress as of the first of October, made its debut earlier this month at an afternoon symposium and reception on Capitol Hill that featured Harold Varmus, a microbiologist at the University of California, San Francisco

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON--The latest battlefield in the ongoing war over priorities within the biomedical research community is the congressional Biomedical Research Caucus. The caucus, which has signed up 18 members of Congress as of the first of October, made its debut earlier this month at an afternoon symposium and reception on Capitol Hill that featured Harold Varmus, a microbiologist at the University of California, San Francisco, and a 1989 Nobel laureate in medicine, and Leon Rosenberg, dean of the Yale University School of Medicine.

Varmus and Rosenberg were joined by Cori Bargman, an academic biochemist just about to start her own lab. Together the three scientists made the case for the value of biomedical research in saving lives and lowering health care costs. Their message--that basic research is an unalloyed good that should receive greater support from the federal government--is one that few people would oppose.

But events in Washington aren't always ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies